Non-transfusion dependent beta-thalassemia (NTDT)

Clinical trials for Non-transfusion dependent beta-thalassemia (NTDT) explained in plain language.

Never miss a new study

Get alerted when new Non-transfusion dependent beta-thalassemia (NTDT) trials appear

Sign up with your email to follow new studies for Non-transfusion dependent beta-thalassemia (NTDT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug aims to tackle iron overload in thalassemia patients

Disease control Ongoing

This Phase 2 trial tests an experimental drug called REGN7999 in about 95 people with non-transfusion dependent beta-thalassemia who have too much iron in their bodies. The drug is given as a shot under the skin and aims to safely reduce iron levels in the liver. Researchers will…

Matched conditions: NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA (NTDT)

Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control

Last updated Jul 03, 2026 00:00 UTC

Non-transfusion dependent beta-thalassemia (NTDT)

Get alerted when new Non-transfusion dependent beta-thalassemia (NTDT) trials appear

New drug aims to tackle iron overload in thalassemia patients